Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26


Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis.

Land J, Lintermans LL, Stegeman CA, Muñoz-Elías EJ, Tarcha EJ, Iadonato SP, Heeringa P, Rutgers A, Abdulahad WH.

Front Immunol. 2017 Sep 26;8:1205. doi: 10.3389/fimmu.2017.01205. eCollection 2017.


B cells and their cytokine activities implications in human diseases.

Fillatreau S.

Clin Immunol. 2018 Jan;186:26-31. doi: 10.1016/j.clim.2017.07.020. Epub 2017 Jul 21.


Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials.

Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, Yu M.

BMJ Open. 2017 Mar 22;7(3):e012567. doi: 10.1136/bmjopen-2016-012567. Review.


B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease.

Koff JL, Flowers CR.

Expert Rev Hematol. 2016 Jun;9(6):553-61. doi: 10.1080/17474086.2016.1180972. Epub 2016 May 13. Review.


Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis.

Chen X, Zhao Q, Hou Y, Jiang J, Zhong W, Wang W, Yao X, Li L, Fang J, Zhang F, Hu P.

Br J Clin Pharmacol. 2016 Jul;82(1):41-52. doi: 10.1111/bcp.12908. Epub 2016 Apr 7.


Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis.

Li R, Rezk A, Healy LM, Muirhead G, Prat A, Gommerman JL, Bar-Or A; MSSRF Canadian B cells in MS Team.

Front Immunol. 2016 Jan 8;6:626. doi: 10.3389/fimmu.2015.00626. eCollection 2015. Review.


Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study.

Schiff M, Combe B, Dörner T, Kremer JM, Huizinga TW, Veenhuizen M, Gill A, Komocsar W, Berclaz PY, Ortmann R, Lee C.

RMD Open. 2015 Aug 12;1(1):e000037. doi: 10.1136/rmdopen-2014-000037. eCollection 2015.


B-cell survival factors in autoimmune rheumatic disorders.

Morais SA, Vilas-Boas A, Isenberg DA.

Ther Adv Musculoskelet Dis. 2015 Aug;7(4):122-51. doi: 10.1177/1759720X15586782. Review.


Profile of atacicept and its potential in the treatment of systemic lupus erythematosus.

Cogollo E, Silva MA, Isenberg D.

Drug Des Devel Ther. 2015 Mar 5;9:1331-9. doi: 10.2147/DDDT.S71276. eCollection 2015. Review. Erratum in: Drug Des Devel Ther. 2015;9:1865. Cogollo, Estafania [corrected to Cogollo, Estefania].


Surface APRIL Is Elevated on Myeloid Cells and Is Associated with Disease Activity in Patients with Rheumatoid Arthritis.

Weldon AJ, Moldovan I, Cabling MG, Hernandez EA, Hsu S, Gonzalez J, Parra A, Benitez A, Daoud N, Colburn K, Payne KJ.

J Rheumatol. 2015 May;42(5):749-59. doi: 10.3899/jrheum.140630. Epub 2015 Mar 1.


Novel therapies for memory cells in autoimmune diseases.

Bhargava P, Calabresi PA.

Clin Exp Immunol. 2015 Jun;180(3):353-60. doi: 10.1111/cei.12602. Epub 2015 Apr 23. Review.


Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.

Lenert A, Lenert P.

Drug Des Devel Ther. 2015 Jan 7;9:333-47. doi: 10.2147/DDDT.S67264. eCollection 2015. Review.


Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor.

Manetta J, Bina H, Ryan P, Fox N, Witcher DR, Kikly K.

J Inflamm Res. 2014 Aug 20;7:121-31. doi: 10.2147/JIR.S67751. eCollection 2014.


Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D.

Ann Rheum Dis. 2015 Nov;74(11):2006-15. doi: 10.1136/annrheumdis-2013-205067. Epub 2014 Jun 20. Erratum in: Ann Rheum Dis. 2016 May;75(5):946.


Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis.

Maseda D, Bonami RH, Crofford LJ.

Expert Rev Clin Immunol. 2014 Jun;10(6):747-62. doi: 10.1586/1744666X.2014.907744. Epub 2014 Apr 16. Review.


Emerging immunotherapies for rheumatoid arthritis.

Reynolds G, Cooles FA, Isaacs JD, Hilkens CM.

Hum Vaccin Immunother. 2014;10(4):822-37. Epub 2014 Feb 17. Review.


Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.

Paula FS, Alves JD.

Biologics. 2014;8:1-12. doi: 10.2147/BTT.S35475. Epub 2013 Dec 9. Review.


Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics.

Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao SW, Lencer WI, Pierce GF, Blumberg RS.

Crit Rev Biotechnol. 2015 Jun;35(2):235-54. doi: 10.3109/07388551.2013.834293. Epub 2013 Oct 24. Review.


B-cell targeted therapeutics in clinical development.

Blüml S, McKeever K, Ettinger R, Smolen J, Herbst R.

Arthritis Res Ther. 2013;15 Suppl 1:S4. doi: 10.1186/ar3906. Epub 2013 Apr 4. Review.

Supplemental Content

Support Center